Associated Papers
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy.
Febres-Aldana CA et al.
Cancer Discovery, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_11_suppst11.pdf
Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors.
Shen B et al.
Future Oncology (london, England), 2019
Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
Du J et al.
Oncotarget, 2017
28460431 (PubMed )
Supplement: oncotarget-08-26281-s001.pdf
Select a paper to view details